Evaluation of the prognostic utility of bone marrow biopsy in diffuse large B-Cell lymphoma in the SEER-Medicare dataset
| Autor: | Peter Martin, John P. Leonard, Sarah C. Rutherford, Jordan S. Goldstein, Danny Luan, Yiyuan Wu |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Cancer Research
medicine.medical_specialty Biopsy Seer medicare Medicare 03 medical and health sciences 0302 clinical medicine immune system diseases Bone Marrow Fluorodeoxyglucose F18 hemic and lymphatic diseases Positron Emission Tomography Computed Tomography medicine Humans Positron emission Positron Emission Tomography-Computed Tomography Aged Retrospective Studies medicine.diagnostic_test business.industry Hematology medicine.disease Prognosis United States Lymphoma medicine.anatomical_structure Oncology 030220 oncology & carcinogenesis Positron-Emission Tomography Radiology Bone marrow Tomography Lymphoma Large B-Cell Diffuse business Diffuse large B-cell lymphoma 030215 immunology |
| Zdroj: | Leukemialymphoma. 62(8) |
| ISSN: | 1029-2403 |
| Popis: | Positron emission tomography-computed tomography (PET-CT) has become the primary modality for staging in diffuse large B-cell lymphoma (DLBCL), whereas the role of staging bone marrow biopsy (BMB) has become less clear. In this analysis, we included 7,005 DLBCL patients in SEER-Medicare who received either PET-CT without BMB (PET-CT w/o BMB), CT with BMB (CT w/ BMB), or both PET-CT and BMB (PET-CT w/ BMB). The proportion of patients undergoing PET-CT increased across years of diagnosis, while the proportion undergoing CT or BMB decreased. In a fully adjusted Cox proportional hazards model, PET-CT w/ BMB was associated with a marginally superior OS compared to PET-CT w/o BMB. Notably, the association between PET-CT w/ BMB and OS was strongest in patients ≤70 years, but was not present when looking at individual stage of diagnosis. Overall, these data do not provide sufficient support to eliminate staging BMB in patients who undergo PET-CT. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|